Burning Rock Biotech Limited (BNR)
| Previous close | 0.7700 |
| Open | 0.8190 |
| Bid | 0.5391 x 200 |
| Ask | 1.0700 x 200 |
| Day's range | 0.8190 - 0.8190 |
| 52-week range | 0.5720 - 2.9500 |
| Volume | |
| Avg. volume | 53,393 |
| Market cap | 84.019M |
| Beta (5Y monthly) | 0.18 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.9000 |
| Earnings date | 28 May 2024 - 03 Jun 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.02 |
GlobeNewswireBurning Rock Publishes 2023 Annual Report on Form 20-F
GUANGZHOU, China, April 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing technology in the field of precision oncology, announces that on April 29, 2024 it filed its Annual Report on Form 20-F for the year ended December 31, 2023 (the “Form 20-F”) with the U.S. Securities and Exchange Commission (“SEC”). The Form 20-F is available for viewing on the SEC website
- GlobeNewswire
Burning Rock Announces ADS Ratio Change
GUANGZHOU, China, April 26, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will change the ratio of its American depositary shares (the “ADSs”) to Class A ordinary shares from one (1) ADS representing one (1) Class A ordinary share to one (1) ADS representing ten (10) Class A ordinary sh
- Thomson Reuters StreetEvents
Q4 2023 Burning Rock Biotech Ltd Earnings Call
Q4 2023 Burning Rock Biotech Ltd Earnings Call
